Enanta Pharmaceuticals (ENTA) Interest Coverage Ratio (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported Interest Coverage Ratio of 3.57 for Q1 2026, up 75.02% on a YoY basis from 2.04 in Q1 2025, and up 2.08% quarter-over-quarter from 3.65 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported Interest Coverage Ratio for 10 years, with the latest figure at 3.57 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 75.02% year-over-year to 3.57; the trailing twelve-month figure through Mar 2026 stood at 5.8 (up 51.05% YoY), and the FY2025 full-year result was 11.11, changed 0.11% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 3.57, up from 3.65 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 3.57 in Q1 2026, with the low at 18.38 in Q2 2023.
- Historically, Interest Coverage Ratio has averaged 10.49 across 4 years, with a median of 10.92 in 2024.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio decreased 18.36% — and 2026, when it jumped 75.02%.
- Enanta Pharmaceuticals' Interest Coverage Ratio stood at 10.14 in 2023, then retreated by 18.36% to 12.0 in 2024, then soared by 69.58% to 3.65 in 2025, then grew by 2.08% to 3.57 in 2026.
- The last three Interest Coverage Ratio figures came in at 3.57 (Q1 2026), 3.65 (Q4 2025), and 7.7 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -3.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.57 |
| Dec 31, 2025 | -3.65 |
| Sep 30, 2025 | -7.70 |
| Jun 30, 2025 | -11.68 |
| Mar 31, 2025 | -14.31 |
| Dec 31, 2024 | -12.00 |
| Sep 30, 2024 | -11.57 |
| Jun 30, 2024 | -10.27 |
| Mar 31, 2024 | -12.78 |
| Dec 31, 2023 | -10.14 |
| Sep 30, 2023 | -9.85 |
| Jun 30, 2023 | -18.38 |
| Dec 31, 2017 | 1,597.44 |
| Sep 30, 2017 | 6,032.78 |
| Jun 30, 2017 | -1,193.55 |
| Mar 31, 2017 | -1,188.25 |
| Dec 31, 2016 | -587.17 |
| Sep 30, 2016 | -281.73 |
| Jun 30, 2016 | -99.00 |
| Mar 31, 2016 | -51.36 |